RenovoRx Q2 net loss holds at $2.91 million; revenue more than doubled to $909,000 year over year - RNXT News | RalliesRenovoRx Q2 net loss holds at $2.91 million; revenue more than doubled to $909,000 year over year
R
RNXT• Clinical trial update
- The Phase III TIGeR-PaC trial reached full enrollment, with topline data expected in H2 2027.
Q2 revenue and profitability
- RenovoRx posted Q2 revenue of USD 909,000, up 61% sequentially, with gross margin of about 84%.
- Net loss was USD 2.9 million, little changed year over year; loss per share narrowed to USD 0.06.
- SG&A climbed to USD 2.9 million; R&D eased to USD 1.2 million.
Guidance and commercial progress
- The company raised 2026 revenue guidance to USD 3.75 million-USD 4.25 million, citing accelerating commercial adoption and repeat ordering.
- RenovoRx ended Q2 with 21 active commercial cancer centers.
APHP
•
